SCHEMBL25770348

SCHEMBL25770348

CC(C)(C)OC(=O)NCCCCOCCCCN=[N+]=[N-]

nearest known ligand 0.51

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
TDP1 Q9NUW8 1/20 0.51
CA12 O43570 6/20 0.50
CA1 P00915 6/20 0.50
CA2 P00918 6/20 0.50
CA9 Q16790 6/20 0.50
MAOA P21397 1/20 0.46
MAOB P27338 1/20 0.46
MEN1 O00255 1/20 0.46
GAA P10253 1/20 0.46
KMT2A Q03164 1/20 0.46
EPHX1 P07099 1/20 0.38
HTT P42858 1/20 0.35
TLR2 O60603 1/20 0.35
TLR1 Q15399 1/20 0.35
STK17B O94768 1/20 0.35
STK17A Q9UEE5 1/20 0.35
CYP3A4 P08684 1/20 0.35
NPSR1 Q6W5P4 1/20 0.35
KDM4E B2RXH2 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21107166 0.99 TDP1 (0.54) TDP1CA12CA1CA2CA9
SCHEMBL21106609 0.97 TDP1 (0.52) TDP1CA12CA1CA2CA9
SCHEMBL25957539 0.97 TDP1 (0.52) TDP1CA12CA1CA2CA9
SCHEMBL25756209 0.97 TDP1 (0.48) TDP1CA12CA1CA2CA9
SCHEMBL25756346 0.96 TDP1 (0.50) TDP1CA12CA1CA2CA9
SCHEMBL31021635 0.93 TDP1 (0.43) TDP1CA12CA1CA2CA9
SCHEMBL31739284 0.93 TDP1 (0.47) TDP1CA12CA1CA2CA9
SCHEMBL15798200 0.93 TDP1 (0.58) TDP1CA12CA1CA2CA9
SCHEMBL31021590 0.92 TDP1 (0.46) TDP1CA12CA1CA2CA9
SCHEMBL13658542 0.92 TDP1 (0.48) TDP1CA12CA1CA2CA9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230210999-A1 TARGETED PROTEASE DEGRADATION (TED) PLATFORM EUBULUS BIOTHERAPEUTICS (HONG KONG) LIMITED (HK) 2023-07-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230210999-A1 TARGETED PROTEASE DEGRADATION (TED) PLATFORM UCHL3, UBE2L3, ADAM33 TDP1 1380/4885CA12 1438/4885CA1 1931/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.